Cephalon adding new details about development programs

Hot on the heels of an FDA approval for its narcolepsy drug Nuvigil, Cephalon has been outlining its plans to expand the use of Nuvigil prior to a commercial launch as it further develops programs for fatigue and pain. In advance of the company's R&D day today, analysts were speculating about Cephalon's likely announcement to expand the use of Fentora for pain and focus on its oncology pipeline. The buzz has investors interested. Buyers helped push up the value of Cephalon's shares in the discussion.

- read the AP report on Cephalon

Related Articles:
Cephalon takes careful approach to Nuvigil. Report
FDA approves Fentora for cancer pain. Report
Cephalon takes heat for off-label narcotic promotion. Report